Unique ID issued by UMIN | UMIN000037123 |
---|---|
Receipt number | R000042296 |
Scientific Title | Evaluation of the efficacy and safety of romosozumab alone and romosozumab + denosumab combination for patients with osteoporosis treated with 2-year denosumab |
Date of disclosure of the study information | 2019/06/20 |
Last modified on | 2019/06/19 23:02:41 |
Evaluation of the efficacy and safety of romosozumab alone and romosozumab + denosumab combination for patients with osteoporosis treated with 2-year denosumab
Evaluation of the efficacy and safety of romosozumab alone and romosozumab + denosumab combination for patients with osteoporosis treated with 2-year denosumab
Evaluation of the efficacy and safety of romosozumab alone and romosozumab + denosumab combination for patients with osteoporosis treated with 2-year denosumab
Evaluation of the efficacy and safety of romosozumab alone and romosozumab + denosumab combination for patients with osteoporosis treated with 2-year denosumab
Japan |
osteoporosis
Orthopedics |
Others
NO
The objective of this study is to examine the efficacy and safety of the two treatments of romosozumab alone and romosozumab plus denosumab after 2 years of treatment with osteoporosis for osteoporosis patients.
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
Bone mineral density at 12 months after treatment
Occurrence of hypocalcemia
Occurrence of other adverse events
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
YES
NO
Institution is considered as a block.
YES
No need to know
2
Treatment
Medicine |
romosozumab plus active vitamin D group
romosozumab + denosumab plus active vitamin D group
20 | years-old | <= |
Not applicable |
Male and Female
1:All osteoporosis patients over 20 years old or older (but does not correspond to the following exclusion criteria)3
2: Patients who have already received Denosumab (60 mg once every 6 months) for 2 years before the start of the study and have a YAM value of 70% or more or a bone density value of less than -2.5 SD
3:Patients who agree with this study
1:Patients who have taken romosozumab or denosumab before
2:Patients who are allergic to romosozumab or denosumab or eldecalcitol
3:Hypocalcemia
4:Pregnant or breast-feeding patients
5:Patients with severe renal function (eGFR 30 ml / min / 1.73 m2) or patients undergoing dialysis
6:Patients at risk of hypercalcemia (patients with renal dysfunction, patients with malignancy, patients with primary hyperparathyroidism)
7:Patients with severe liver dysfunction
8:Patients with urolithiasis and patients with a history of their history
60
1st name | Yukio |
Middle name | |
Last name | Nakamura |
Shinshu University School of Medicine
Dept. of Orthopaedic Surgery
390-8621
Asahi 3-1-1, Matsumoto 3908621, Japan
0263372659
yxn14@aol.jp
1st name | Yukio |
Middle name | |
Last name | Nakamura |
Shinshu University School of Medicine
Dept. of Orthopaedic Surgery
390-8621
Asahi 3-1-1, Matsumoto 3908621, Japan
0263372659
yxn14@aol.jp
Shinshu University School of Medicine
Dept. of Orthopaedic Surgery
Shinshu University School of Medicine
Dept. of Orthopaedic Surgery
Self funding
Shinshu University School of Medicine Dept. of Orthopaedic Surgery
Asahi 3-1-1, Matsumoto 3908621, Japan
0263372659
yxn14@aol.jp
NO
2019 | Year | 06 | Month | 20 | Day |
Partially published
Preinitiation
2019 | Year | 06 | Month | 06 | Day |
2019 | Year | 06 | Month | 10 | Day |
2019 | Year | 06 | Month | 20 | Day |
2021 | Year | 06 | Month | 03 | Day |
2024 | Year | 06 | Month | 03 | Day |
2019 | Year | 06 | Month | 20 | Day |
2019 | Year | 06 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042296